Atezolizumab was added to this combination in each of eight initial cycles before maintenance therapy without oxaliplatin and irinotecan; however, 6–7% of subjects had MMR-deficient CRC which may have accounted for the significantly improved PFS in the experimental group. Here, MRC1 is linked to colorectal carcinoma.